Open AccessLow rates of nucleoside reverse transcriptase inhibitor and nonnucleoside reverse transcriptase inhibitor drug resistance in Botswana
Author(s) -
Sikhulile Moyo,
Simani Gaseitsiwe,
Melissa Zahralban-Steele,
Dorcas Maruapula,
Tapiwa Nkhisang,
Baitshepi Mokaleng,
Terence Mohammed,
Tsotlhe R. Ditlhako,
Ontlametse T. Bareng,
Thatayaone P. Mokgethi,
Erik van Widenfelt,
Molly Pretorius-Holme,
Madisa Mine,
Elliot Raizes,
Etienne Kadima Yankinda,
Kathleen Wirth,
Tendani Gaolathe,
Joseph Makhema,
Shahin Lockman,
Max Essex,
Vlad Novitsky
Publication year - 2019
Publication title -
aids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.195
H-Index - 216
eISSN - 1473-5571
pISSN - 0269-9370
DOI - 10.1097/qad.0000000000002166
Subject(s) - reverse transcriptase , reverse transcriptase inhibitor , drug resistance , virology , hiv drug resistance , nucleoside reverse transcriptase inhibitor , population , viral load , medicine , confidence interval , resistance mutation , biology , human immunodeficiency virus (hiv) , antiretroviral therapy , polymerase chain reaction , genetics , environmental health , gene
Scale-up of antiretroviral therapy (ART) and introduction of treat-all strategy necessitates population-level monitoring of acquired HIV drug resistance (ADR) and pretreatment drug resistance (PDR) mutations.